Accessibility Statement

Press Releases


Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer

October 8, 2024

Tags |  Corporate General

<p>INDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, effective Oct. 21, 2024. In this role, Fuchs will provide vision, strategic direction and overall leadership of AI initiatives across Lilly,</p>




Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

October 2, 2024

Tags |  Corporate

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more




Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

September 12, 2024

Tags |  Corporate

Company ups manufacturing investment in Limerick by $1 billion ; unveils new $800 million&nbsp;Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS , Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:&nbsp;LLY) today




Lilly appoints Lucas Montarce as executive vice president and chief financial officer

September 9, 2024

Tags |  Corporate

INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:&nbsp;LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.




Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

September 4, 2024

Tags |  Corporate

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa INDIANAPOLIS and CAIRO , Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and&nbsp;




Lilly announces retirement of Marschall S. Runge from its Board of Directors

August 16, 2024

Tags |  Corporate

INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge , M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024 . Dr. Runge has served on Lilly's board since 2013,




Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

August 16, 2024

Tags |  Corporate

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)




Lilly opens state-of-the-art research and development center in the Boston Seaport

August 13, 2024

Tags |  Corporate

Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway




Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

July 8, 2024

Tags |  Corporate

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic , a




Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria

June 25, 2024

Tags |  Corporate

INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public